Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- solid plates 17-phenyl-trinor-PGF2alpha prostaglandins 17-phenyl-trinor-PGF2.alpha. measures kits eias enzyme immunoassays ELISAs EIA assays
- Product Overview:
17-phenyl trinor Prostaglandin F2? (17-phenyl trinor PGF2?) is a metabolically stable analog of PGF2? and is a potent agonist for the FP receptor. It binds to the FP receptor on ovine luteal cells with a relative potency of 756% compared to that of PGF2?.{2058} At the rat recombinant FP receptor expressed in CHO cells, 17-phenyl trinor PGF2? inhibits PGF2? binding with a Ki value of 1.1 nM.{1374} In human and animal models of glaucoma, FP receptor agonist activity corresponds very closely with intraocular hypotensive activity. 17-phenyl trinor PGF2? ethyl amide is an F-series prostaglandin analog which has been approved for use as an ocular hypotensive drug, sold under the Allergan trade name Bimatoprost.{8941} Whether 17-phenyl trinor PGF2? ethyl amide is a prodrug analogous to prostaglandin ester prodrugs such as latanoprost is currently controversial. There is some evidence that unmetabolized 17-phenyl trinor PGF2? is a weak FP receptor agonist.{9581} 17-phenyl trinor PGF2? is converted by an amidase enzymatic activity in the bovine and human cornea to yield the corresponding free acid, with a conversion rate of about 40 µg/g corneal tissue/24 hours.{9311} Cayman’s 17-phenyl trinor PGF2? ELISA is a sensitive detection method for measuring both the free acid and ethyl amide forms of 17-phenyl trinor PGF2?. The assay is most appropriate for use when only one of the two forms is present. Samples containing mixtures of both the ethyl amide and free acid should be purified and the two compounds separated prior to ELISA analysis.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.